University of North Carolina

SEABOARD FOODS NAMES CHAD GROVES AS PRESIDENT AND CEO TO SUCCEED PETER BROWN AFTER RETIREMENT

Retrieved on: 
Monday, March 25, 2024
High Liner Foods, Butterball, University, Treasurer, MBA, Marketing, University of North Carolina, National Pork Board, Retirement, Purdue University, Management

MERRIAM, Kan., March 25, 2024 /PRNewswire/ -- Seaboard Corporation (NYSE American: SEB) today announced that it has named Chad Groves as the next President and Chief Executive Officer of its pork division, Seaboard Foods LLC (Seaboard Foods), to succeed Seaboard Foods' current President and Chief Executive Officer, Peter Brown, who announced that he will be retiring, effective June 28, 2024.

Key Points: 
  • MERRIAM, Kan., March 25, 2024 /PRNewswire/ -- Seaboard Corporation (NYSE American: SEB) today announced that it has named Chad Groves as the next President and Chief Executive Officer of its pork division, Seaboard Foods LLC (Seaboard Foods), to succeed Seaboard Foods' current President and Chief Executive Officer, Peter Brown, who announced that he will be retiring, effective June 28, 2024.
  • Mr. Brown joined Seaboard Foods in January 2021 after more than 30 years of executive leadership experience in the protein industry, including leadership positions with Butterball and High Liner Foods.
  • Seaboard would like to thank Mr. Brown for his leadership of the organization over the past three years.
  • Before joining Seaboard Foods, Mr. Groves was most recently the Vice President of Sales – Retail & Foodservice at Trilliant Food & Nutrition LLC and, prior to that, Vice President of Field Sales – Foodservice at High Liner Foods.

Lawsuit Challenges NCAA's Prize Money Restrictions

Retrieved on: 
Tuesday, March 19, 2024
National Collegiate Athletic Association, Sport, Tennis, NCAA, District court, UNC, University, Life, Athlete, University of North Carolina, Partnership

The lawsuit asks a U.S. District Court to strike down the NCAA's restrictions on student-athletes' acceptance of prize money earned in non-NCAA competitions.

Key Points: 
  • The lawsuit asks a U.S. District Court to strike down the NCAA's restrictions on student-athletes' acceptance of prize money earned in non-NCAA competitions.
  • The NCAA's longstanding "amateurism" rules prohibit student-athletes from accepting prize money earned primarily through participation in non-NCAA competitions, such as the U.S. Open Tennis Championships, the U.S. Open Golf Championship, the U.S.
  • Reese does not seek money but aims to eliminate the NCAA's illegal and arbitrary restrictions," said Peggy Wedgworth, a Senior Partner at Milberg.
  • Through attorneys with Milberg and Miller Monroe & Plyler, Brantmeier is seeking an injunction prohibiting the NCAA from enforcing its anticompetitive and unlawful rules restricting student-athletes' acceptance of prize money earned in non-NCAA competitions.

ACTG Presents Study at CROI Demonstrating Efficacy of Long-Acting Injectable Treatment Among People Who Had Previously Been Unable to Maintain Viral Suppression on Daily Oral Medication

Retrieved on: 
Wednesday, March 6, 2024
Infection, Chair, Bangladesh Technical Education Board, Mental health, Injection (medicine), University of Alabama, Rilpivirine, Fungal infection, NIAID, Arm, CROI, PWH, Quality of life, ACTG, Johnson & Johnson, Data monitoring committee, Conference, Health, University, ART, UM1, Male, DSMB, ViiV Healthcare, HIV, Failure, University of North Carolina, Vaccine

“ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

Key Points: 
  • “ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.
  • Participants received incentives and support to adhere to their daily oral medication to first achieve viral suppression and if successful, they were randomized to either receive long-acting injectable treatment every four weeks or continue taking daily oral medication.
  • The long-acting injectable treatment was more effective than the daily oral medication at maintaining virologic suppression and avoiding treatment-related discontinuation.
  • Twenty-eight participants receiving the long-acting injectable treatment experienced regimen failure (defined as virologic failure or treatment discontinuation), compared to 47 receiving daily oral medication.

ACTG CROI Presentation Demonstrates Superiority of HepB-CpG Vaccine Over Conventional Hepatitis B Vaccine Among People Living With HIV Who Have Not Previously Responded to Vaccination

Retrieved on: 
Wednesday, March 6, 2024
Infection, Bangladesh Technical Education Board, CD4, Superior, Hepatitis B, Headache, CpG, Fungal infection, NIAID, CROI, ACTG, University of Cincinnati, Weill Cornell Medicine, Conference, Vaccination, University, ART, Fatigue, Virus, Myalgia, White, Black, Protocol, UM1, Massachusetts General Hospital, Male, Hepatitis, HIV, University of North Carolina, Vaccine

These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.

Key Points: 
  • These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.
  • People living with HIV, especially those with lower CD4 counts, often do not develop protective antibodies after receiving conventional hepatitis B vaccines.
  • The HepB-CpG (HEPLISAV-B®) vaccine includes a TLR-9 agonist adjuvant (CpG 1018® adjuvant) and is known to achieve high protection against hepatitis B among people living with HIV, but until now there have been limited data about its protection among people living with HIV who have not responded to conventional hepatitis B vaccines.
  • “Hepatitis B remains a significant issue for people living with HIV, as having both viruses increases the likelihood of liver complications,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

ACTG CROI Presentations Show That Semaglutide Improves Metabolic-Associated Steatotic Liver Disease Among People Living With HIV

Retrieved on: 
Tuesday, March 5, 2024
Infection, Liver, Bangladesh Technical Education Board, Metabolism, Woman, P.T, Fungal infection, NIAID, Prediabetes, CROI, Liver injury, Inflammation, Quality of life, ACTG, ALT, Weight loss, Waist, Weight, Organ dysfunction, University of Southern California, Conference, Health, Glucagon-like peptide-1 receptor, University, SLIM, ART, Triglyceride, BMI, UM1, Insulin resistance, HIV, Non-alcoholic fatty liver disease, Research, University of North Carolina, Dietary supplement

Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.

Key Points: 
  • Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.
  • Together, these presentations demonstrate that semaglutide was highly effective in improving, and in some cases, resolving completely, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease) among people living with HIV.
  • SLIM LIVER is the first study evaluating semaglutide as a treatment for MASLD among people living with HIV.
  • MASLD is common among people living with HIV and likely acts synergistically with HIV to accelerate liver injury and organ dysfunction.

ACTG Presents Study at CROI Elucidating Mechanism of CMV on Aging-Related Pathways in HIV

Retrieved on: 
Monday, March 4, 2024
Infection, Chairperson, Bangladesh Technical Education Board, Diabetes, CMV, Metabolism, Merck, Cancer, Endothelial dysfunction, Fungal infection, NIAID, CROI, Inflammation, Blood, IL-6, Ageing, ACTG, Splenic infarction, Risk, Conference, Cytomegalovirus, University, ART, Biomarker, Merck & Co., University of California, UM1, Insulin resistance, Poster, Letermovir, Probability, Atherosclerosis, Plasma, TNF, HIV, University of North Carolina, Immune system, Brain

CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.

Key Points: 
  • CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.
  • Prior to the availability of effective antiretroviral therapy (ART) for HIV, CMV caused life-threatening infections in the eyes, brain, and gut in people with compromised immune systems due to advanced HIV.
  • “Investigators have found associations between CMV and heart disease, cancer, and other aging-related complications among people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

Prevent Cancer Foundation awards $1 million in new research grants

Retrieved on: 
Wednesday, February 21, 2024
Head, Breast cancer, Neck, Cancer, Woman, Survivor, Diet, Reproductive medicine, Assistant, Melanoma, Blood, Uterus, Biostatistics, Skin, Immunodeficiency, Database, Communication, Risk, FACP, Breast, University, Stomach, Vaccination, MD Anderson Cancer Center, Member of Congress, Genetic, Dicarboxylic acid, Drinking, Ovarian cancer, Genetics, Squamous-cell carcinoma, Death, Associate, Genetic testing, Black, Huntsman Cancer Institute, SCCS, Disease, HPV, Knowledge, Health literacy, Mortality, New York University, Research, University of North Carolina, Partnership, Birth control

Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.

Key Points: 
  • Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.
  • Read on for more on the 2024 research grantees or access more detailed information on their projects in the researcher database.
  • Having a family history of cancer can affect the age at which cancer screening begins and genetic testing recommendations.
  • To view all past funded research grant and fellowship projects driving these key advancements in cancer prevention and early detection, explore the Prevent Cancer Foundation’s Award Database.

Marriott Bonvoy Celebrates Passion of Sports Fans With Game Day Rituals Campaign and Contest Ahead of NCAA March Madness Tournament

Retrieved on: 
Tuesday, February 20, 2024
University of Georgia, Rocket Mortgage FieldHouse, Restaurant, College basketball, NCAA, Key Tower, University of Colorado Boulder, University of California, Berkeley, Rock, Transport, Roam, State Farm Stadium, University of Connecticut, Game day, University of Memphis, Personality, Fairfield Inn, Food, Travel, Risk, University, Texas Tech University, Learfield, University of California, Duke University, UCLA, University of North Carolina, Hotel

BETHESDA, Md., Feb. 20, 2024 /PRNewswire/ -- Marriott Bonvoy® is celebrating its eighth year as the Official Hotel Partner of the NCAA® and the 2024 March Madness® tournament with the launch of its "Score Big with Marriott Bonvoy Game Day Rituals" campaign and contest. Marriott Bonvoy, Marriott International's extraordinary portfolio of over 30 hotel brands, award-winning travel program, and endless experiences, has a brand for every type of fan.

Key Points: 
  • Highlighting the passionate enthusiasm of sports fans, Marriott Bonvoy's "Game Day Rituals" campaign features a variety of NCAA athletes2, coaches, and fans as they prepare for games at various Marriott Bonvoy hotels.
  • "Our Game Day Rituals campaign encapsulates the exceptional travel experiences that Marriott Bonvoy provides for travelers, from sports fans to players and coaches alike," said Mandy Gill, Vice President, Continent Marketing, Marriott International.
  • Ahead of the March Madness tournament, Marriott Bonvoy hotels are gearing up to host fans and players alike for their game day getaways.
  • 1The Marriott Game Day Rituals Survey was conducted by Wakefield Research (wakefieldresearch.com) among 1,000 U.S. sports fans with a game day ritual.

ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis Regimen Among People Living with HIV

Retrieved on: 
Wednesday, February 14, 2024
Infection, Bangladesh Technical Education Board, Tuberculosis, NIAID, Blood, Safety, ACTG, Trial of the century, TB, Risk, University, ART, Rifapentine, University of London, University of California, Johns Hopkins University, UM1, Pharmacokinetics, Diagnosis, Ageing, HIV, Research, University of North Carolina, Pharmaceutical industry

Previously, ACTG study A5349 demonstrated that a four-month, four-drug TB regimen that included high-dose rifapentine was as effective as the standard six-month regimen, cutting the treatment time by one third.

Key Points: 
  • Previously, ACTG study A5349 demonstrated that a four-month, four-drug TB regimen that included high-dose rifapentine was as effective as the standard six-month regimen, cutting the treatment time by one third.
  • “Understanding the relationship between these anti-TB and HIV medications is crucial, as an estimated one third of people living with HIV worldwide are at risk for developing TB,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • Dolutegravir is being supplied to study A5406 by ViiV Healthcare Ltd and the fixed-dose combination of dolutegravir/tenofovir disoproxil fumarate/lamivudine is being supplied by Viatris.
  • The ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice Chair).

Rutgers Appoints 33 Research Fellows to Study a Key Gateway to Wealth for the Middle Class: Employee Share Ownership

Retrieved on: 
Tuesday, February 13, 2024
Human Resources, Labor, Consulting, Public Policy, Government, Professional Services, Philanthropy, University, Foundation, Education, Fellow, Democrat, Workplace, Cooperative, Social, Employee stock ownership, Harvard Law School, Rutgers University, History, Associate, Knowledge, Joseba Azkarraga, Past, Research, University of North Carolina, University of Minnesota

The Rutgers Institute for the Study of Employee Ownership and Profit Sharing has announced the appointment of 33 research fellows to join its global network of scholars and subject matter experts.

Key Points: 
  • The Rutgers Institute for the Study of Employee Ownership and Profit Sharing has announced the appointment of 33 research fellows to join its global network of scholars and subject matter experts.
  • They will explore business models that enable workers to build wealth on top of wages, creating new opportunities to strengthen the middle class and close racial and gender wealth gaps.
  • “These fellows are advancing understanding of employee share ownership, profit sharing, and similar tools for sharing wealth and profits, in important ways.
  • The Institute is the world’s leading academic research hub dedicated to employee share ownership, equity compensation, profit sharing, and worker cooperatives.